{"content":"<li class=\"n-box-item date-title\" data-end=\"1540094399\" data-start=\"1540008000\" data-txt=\"Monday, December 23, 2019\">Saturday, October 20, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3399072\" data-ts=\"1540073363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399072-unique-combination-of-opdivo-yervoy-shows-encouraging-action-in-phase-1-2-bladder-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17306664-opdivo-nivolumab-combination-yervoy-ipilimumab-shows-promising-results-patients-advanced-form\" target=\"_blank\">Follow-up data</a> from a Phase 1/2 clinical trial, CheckMate-032, evaluating Bristol-Myers Squibb's (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) Opdivo (nivolumab) + Yervoy (ipilimumab) in patients with platinum-resistant metastatic urothelial carcinoma (advanced form of bladder cancer) showed a positive treatment effect. The results were presented at ESMO in Munich.</li><li>At a minimum follow-up of 7.9 months, patients receiving 1 mg/kg of Opdivo and 3 mg/kg of Yervoy (O1:Y3) showed an overall response rate &#40;ORR&#41; of 38%. At a minimum follow-up of 38.8 months, patients receiving 3 mg/kg of Opdivo and 1 mg/kg of Yervoy (O3:Y1) showed an ORR of 27%. At a minimum follow-up of 37.7 months, patients receiving Opdivo alone showed an ORR of 26%.</li><li>Median progression-free survival &#40;PFS&#41; and overall survival &#40;OS&#41; in the three arms were 4.9 months and 15.3 months, 2.6 months and 7.4 months and 2.8 months and 9.9 months, respectively.</li><li>No new safety signals were observed.</li><li>The data support the ongoing Phase 3&nbsp;<a href=\"https://clinicaltrials.gov/ct2/show/NCT03036098?titles=checkmate-901&amp;lead=bristol-myers+squibb&amp;rank=1\" target=\"_blank\">CheckMate-901</a> study in treatment-naive bladder cancer patients.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399072\" data-linked=\"Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study\" data-tweet=\"$BMY - Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study https://seekingalpha.com/news/3399072-unique-combination-of-opdivo-yervoy-shows-encouraging-action-in-phase-1-2-bladder-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3399072-unique-combination-of-opdivo-yervoy-shows-encouraging-action-in-phase-1-2-bladder-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399070\" data-ts=\"1540071530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399070-pareteum-files-for-150m-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum files for $150M mixed shelf offering</a></h4><ul><li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1084384/000114420418054604/tv505044_s3.htm\" target=\"_blank\">prospectus </a>for a $150M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399070\" data-linked=\"Pareteum files for $150M mixed shelf offering\" data-tweet=\"$TEUM - Pareteum files for $150M mixed shelf offering https://seekingalpha.com/news/3399070-pareteum-files-for-150m-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3399070-pareteum-files-for-150m-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":2,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}